Ignite Creation Date:
2025-12-25 @ 4:03 AM
Ignite Modification Date:
2026-01-29 @ 9:09 AM
Study NCT ID:
NCT04204902
Status:
COMPLETED
Last Update Posted:
2023-11-08
First Post:
2019-12-17
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Bioequivalence of 5 Tablets of 100 mg Versus 2 Tablets of 250 mg TF3 of Tepotinib
Sponsor:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
MS200095_0038
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None